000108430 001__ 108430 000108430 005__ 20230602121506.0 000108430 0248_ $$2sideral$$a125001 000108430 037__ $$aART-2021-125001 000108430 041__ $$aeng 000108430 100__ $$0(orcid)0000-0002-6546-6149$$aBellés, A.$$uUniversidad de Zaragoza 000108430 245__ $$aNative and saturated bovine lactoferrin modulate the expression of toll-like receptors (TLRS) in mice treated with antibiotics. P0203. 29th United European Gastroenterology Week Virtual 2021 000108430 260__ $$c2021 000108430 5060_ $$aAccess copy available to the general public$$fUnrestricted 000108430 5203_ $$aIntroduction: The gut microbiota plays a fundamental role in protection against pathogen infections but also in the regulation of the immune sys-tem. The antibiotic administration can result in gut microbiota alterations and changes in the eectiveness of innate immune responses. As micro-biota composition changes, the altered community will present dierent microbial-associated molecular patterns to Toll-like receptors (TLRs), which can cascade down through various immune responses, including changes in the expression of TLR receptors [1]. In this context, finding ingredients that can modulate the immune system is becoming a major focus of interest to produce functional foods. Bovine lactoferrin is a milk protein with many biological properties, including an-tibacterial and immunomodulatory activity [2].Aims & Methods: The objective was to determine the eects of native (nLf) and saturated (sLf) bovine lactoferrin on TLR receptor expression of colon from mice treated or untreated with the antibiotic clindamycin, to evalu-ate its potential to be added in functional foods.Male C57BL/6 mice of 8 weeks old were randomly divided into six groups (n=5 per group): vehicle, clindamycin (Clin), native bovine lactoferrin (nLf), nLf + clindamycin (nLf_Clin), iron-saturated bovine lactoferrin (sLf) and sLf + clindamycin (sLf_Clin). Vehicle received saline orally for 10 days. Clin was gavaged for 10 days with saline and on day 4 received a single IP injection of 200 µg of clindamycin. nLf and sLf were gavaged for 10 days with 35 mg of nLf or sLf. The groups nLf_Clin and sLf_Clin were gavaged with nLf or sLf and on day 4 received an injection of clindamycin.The gene expression (mRNA) of TLR1-9 receptors was determined in the colon from mice by RT-PCR and relative expression levels of genes were calculated using the 2 -∆∆CT method.Results: The expression of TLR2, TLR4, TLR5 and TLR6 was not modified in any of the treated groups. The expression of TLR1 was increased in sLf, nLf_Clin and sLf_Clin treated groups, indicating that the eect of sLf on TLR1 expression was maintained despite the treatment with Clin. The expression of TLR8 and TLR9 decreased in Clin, nLf and nLf_Clin groups. However, the levels of these receptors in sLf_Clin were similar to Vehicle, demonstrating the immunomodulatory capacity of sLf to restore these receptor levels, in a situation of intestinal dysbiosis. Finally, respect to TLR3 and TLR7, only the group of mice treated with sLf_Clin showed an increase in the expression of this receptor. Conclusion: Saturated bovine lactoferrin can restore the expression levels of TLR8 and TLR9 in conditions of intestinal dysbiosis induced by antibiot-ics. These results confirm the immunomodulatory properties of lactoferrin, which have great interest for the design of functional foods. 000108430 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/ 000108430 590__ $$a6.866$$b2021 000108430 592__ $$a1.445$$b2021 000108430 594__ $$a7.9$$b2021 000108430 591__ $$aGASTROENTEROLOGY & HEPATOLOGY$$b23 / 92 = 0.25$$c2021$$dQ1$$eT1 000108430 593__ $$aOncology$$c2021$$dQ1 000108430 593__ $$aGastroenterology$$c2021$$dQ1 000108430 655_4 $$ainfo:eu-repo/semantics/conferenceObject$$vinfo:eu-repo/semantics/publishedVersion 000108430 700__ $$0(orcid)0000-0002-1829-6319$$aAguirre-Ramírez, D. 000108430 700__ $$aAbad, I.$$uUniversidad de Zaragoza 000108430 700__ $$0(orcid)0000-0001-5964-823X$$aSánchez, L.$$uUniversidad de Zaragoza 000108430 700__ $$0(orcid)0000-0002-5306-9365$$aGrasa, L.$$uUniversidad de Zaragoza 000108430 7102_ $$11012$$2410$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Fisiología 000108430 7102_ $$12008$$2780$$aUniversidad de Zaragoza$$bDpto. Produc.Animal Cienc.Ali.$$cÁrea Tecnología de Alimentos 000108430 773__ $$g9, 58 (2021), 376$$pUnited European Gastroenterol. j.$$tUnited European Gastroenterology Journal$$x2050-6406 000108430 85641 $$uhttps://onlinelibrary.wiley.com/doi/epdf/10.1002/ueg2.12144$$zTexto completo de la revista 000108430 8564_ $$s202809$$uhttps://zaguan.unizar.es/record/108430/files/texto_completo.pdf$$yVersión publicada 000108430 8564_ $$s1717835$$uhttps://zaguan.unizar.es/record/108430/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000108430 909CO $$ooai:zaguan.unizar.es:108430$$particulos$$pdriver 000108430 951__ $$a2023-06-02-11:02:43 000108430 980__ $$aARTICLE